NASDAQ$HROW
Harrow Inc · Q4 2021 earnings
Q4 2021 earnings · · Investor relations
Briefing
Reported sixth consecutive quarter of record revenues and improved gross margin.
Harrow Health reported record revenues for the fourth quarter of 2021, marking the sixth consecutive quarter of record performance. The company also achieved a gross margin of 75% during the quarter.
- Reported sixth consecutive quarter of record revenues.
- Gross margin improved to 75% for the fourth quarter.
- Filed first New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA).
- Began to realize high-margin revenues from recently acquired FDA-approved branded products.
Headline financials
Revenue & EPS history
Harrow · Revenue · Quarterly
$20.2M
Forward guidance
2022 is shaping up to be a ‘break-out’ year for Harrow Health. In the second quarter of 2022, the company is expecting top-line readouts on clinical studies from two of their non-controlling equity positions, followed in mid-October by a determination by the FDA on their NDA for AMP-100.
Tailwinds
- Expecting top-line readouts on clinical studies from two of our non-controlling equity positions in the second quarter of 2022.
- FDA determination expected in mid-October on NDA for AMP-100.
- Potential commercial launch a few months after FDA approval.
- Focus on growing core ophthalmic pharmaceuticals business.
- Launching new ophthalmic products internally developed.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2021
+1.6%
Avg return
Earnings day
+3.0%
Avg return
5 days after
+8.3%
Avg return
30 days after
52%
25 / 48 earnings
Positive
+49.3%
Q2 2024
Best reaction
-36.0%
Q3 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.4% | -18.5% | -6.3% | |
| Q4 2025 | +2.3% | -32.2% | -34.1% | |
| Q3 2025 | +13.6% | +19.5% | +49.7% | |
| Q1 2025 | +3.4% | +6.5% | +25.4% | |
| Q4 2024 | -6.0% | +21.8% | +2.9% | |
| Q3 2024 | -14.1% | -23.9% | -28.9% | |
| Q2 2024 | +49.3% | +56.3% | +67.2% | |
| Q1 2024 | +40.0% | +44.5% | +57.3% | |
| Q4 2023 | +0.3% | +9.6% | +3.4% | |
| Q3 2023 | -36.0% | -30.2% | -21.7% | |
| Q2 2023 | -17.4% | -14.7% | -26.8% | |
| Q1 2023 | -20.5% | -24.1% | -26.9% | |
| Q4 2022 | +6.7% | +22.9% | +42.6% | |
| Q3 2022 | -4.2% | -9.4% | +10.5% | |
| Q2 2022 | +12.2% | +24.6% | +32.6% | |
| Q1 2022 | +3.3% | -5.3% | +15.3% | |
| Q4 2021 | +3.0% | -1.4% | -1.7% | |
| Q3 2021 | -4.9% | -3.3% | -21.1% | |
| Q2 2021 | -0.3% | -0.8% | +13.0% | |
| Q1 2021 | +15.8% | +14.5% | +14.0% | |
| Q4 2020 | +3.5% | +3.4% | -12.3% | |
| Q3 2020 | +25.8% | +30.0% | +19.9% | |
| Q2 2020 | +4.8% | +10.4% | +15.0% | |
| Q1 2020 | -5.8% | -9.7% | +36.5% | |
| Q4 2019 | -7.5% | -16.0% | -3.8% | |
| Q3 2019 | +18.6% | +16.1% | +33.8% | |
| Q2 2019 | -23.6% | -21.7% | -8.0% | |
| Q1 2019 | +10.1% | +16.5% | +26.6% | |
| Q4 2018 | -7.5% | -20.3% | -30.1% | |
| Q3 2018 | +7.2% | +23.0% | +38.4% | |
| Q2 2018 | +13.4% | +29.3% | +26.4% | |
| Q1 2018 | +9.3% | +5.3% | +6.2% | |
| Q4 2017 | -3.4% | -5.3% | -3.9% | |
| Q3 2017 | +5.7% | +19.1% | +7.6% | |
| Q2 2017 | -7.9% | -9.7% | -28.2% | |
| Q1 2017 | -4.8% | -12.6% | -22.5% | |
| Q4 2016 | +2.9% | +17.0% | +79.7% | |
| Q3 2016 | -9.8% | -13.2% | -28.9% | |
| Q2 2016 | -3.1% | -2.6% | +6.5% | |
| Q1 2016 | +1.9% | — | — | |
| Q4 2015 | -2.2% | — | — | |
| Q3 2015 | -6.2% | — | — | |
| Q2 2015 | -1.3% | — | — | |
| Q1 2015 | +1.3% | — | — | |
| Q4 2014 | +3.5% | — | — | |
| Q3 2014 | -2.7% | — | — | |
| Q2 2014 | +7.8% | — | — | |
| Q2 2010 | -1.0% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro